Real-world assessment of sparsentan's drug safety framework
{{output}}
Background: Sparsentan has been approved for reducing proteinuria in adult patients with primary IgA nephropathy (IgAN) at risk of rapid disease progression, yet comprehensive studies evaluating its drug safety framework are lack... ...
